HybSelect(TM) first to provide high coverage and megabase capacity for the next generation sequencing community
LEXINGTON, Mass. and HEIDELBERG, Germany, March 16 /PRNewswire/ -- febit today announced the official launch of its new sequence capture technology HybSelect. In several biomedical studies of early access customers over the past months, HybSelect demonstrated superb enrichment factors and deep sequencing coverage for a broad range of human genes and genomic regions. As the first sequence capture technology combining outstanding enrichment and walk-away convenience, HybSelect opens up new opportunities in biomarker discovery and the development of personalized medicine.
Declining costs and dramatically higher sequencing output has distinguished the fast-paced genomics market since 2003. Sequencing a human genome, a project that required years and billions of USD, is now feasible in weeks for thousands of USD. Nevertheless, conducting statistically relevant biomedical studies with deep sequencing of patient samples is still prohibitively expensive and inefficient. HybSelect effectively scales next generation sequencing to the needs of biomedical research and discovery by enabling large scale studies.
The accessibility and enormous capacity of the next generation sequencers have triggered a heightened demand for sequence capture technologies amongst geneticists: targeted re-sequencing of medically-relevant genome loci will greatly enhance the understanding of health and disease in crucial areas such as cancer and Alzheimer's disease. The outcomes of such studies are significant in that they will allow improved diagnostics and targeted applications of medical agents.
"HybSelect even enables large scale targeted re-sequencing studies because of the high degree of automation combined with the power to detect genetically relevant info
Copyright©2009 PR Newswire.
All rights reserved